American Society of Hirudotherapy

Ghilanten

Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Ghilanten15 kDa
Molecular weight (kilodaltons) of Ghilanten (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Preclinical (animal)
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Ghilanten's preclinical anticoagulant and anti-metastatic activity does NOT establish clinical efficacy for any indication. No FDA-approved derivative exists; anti-cancer claims rest on animal models alone.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
15,000 Da
Source species
Haementeria ghilianii
Discovered
1990 · Blankenship DT et al.

Biological Targets

  • → Factor Xa

Key Citations

  1. Blankenship DT, Brankamp RG, Manley GD, Cardin AD (1990), Biochem Biophys Res Commun · PMID 2306252
  2. Brankamp RG, Manley GG, Blankenship DT, Bowlin TL, Cardin AD (1991), Blood Coagul Fibrinolysis · PMID 1772984

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.